Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Asia Pacific Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
4.1 Asia Pacific Hormonal Therapy Market by Country
4.2 Asia Pacific Immunotherapy Market by Country
4.3 Asia Pacific Chemotherapy Market by Country
4.4 Asia Pacific Radiotherapy Market by Country
Chapter 5. Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.1 China Castrate-resistant Prostate Cancer Market
5.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.2 Japan Castrate-resistant Prostate Cancer Market
5.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3 India Castrate-resistant Prostate Cancer Market
5.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.4 South Korea Castrate-resistant Prostate Cancer Market
5.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.5 Singapore Castrate-resistant Prostate Cancer Market
5.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.6 Malaysia Castrate-resistant Prostate Cancer Market
5.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
Unique Offerings 